T cell receptor alpha joining 17 (TRAJ17)

TRAJ17 (T cell receptor alpha joining 17) is a **gene segment** encoding the J (joining) region within the T cell receptor alpha locus[2][6]. It is not a standalone protein-coding gene but a DNA sequence that participates in somatic recombination during T lymphocyte development[4]. In the thymus, variable (V), joining (J), and constant (C) segments assemble to produce the functional T cell receptor alpha chain, which is critical for recognizing antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[4]. TRAJ17 itself does not encode a full receptor or protein but serves as a recombination element incorporated into the final T cell receptor structure[2][6]. While essential for immune diversity, TRAJ17 is *not a therapeutic target* and is mostly referenced for immunogenetics and T cell development[2][6]. **Clarification:** - TRAJ17 is often confused with TRAV17 (T cell receptor alpha variable 17), which encodes a part of the variable region of the alpha chain and is a protein-coding gene involved in antigen recognition[1][3][4][9]. TRAJ17 is strictly a joining gene segment[2][6]. - There is no evidence that TRAJ17 is a direct drug target, biomarker, or disease gene, nor does it function independently outside the context of TCR gene rearrangement[2][6]. **Summary judgment:** - The target “TRAJ17” is **not a standalone receptor or therapeutic target**; it is a gene segment required for V(J) recombination of the T cell receptor alpha chain. - The entry is **technically incorrect** if used as a drug target or receptor. For structured drug-target databases, it should be flagged accordingly[2][6].

Other names

TRAJ17